DEF 14A: Glaukos Corp Seeks Stockholder Approval for Amended Incentive Plan and Director Elections

Glaukos Corporation is soliciting proxies for its 2024 Annual Meeting of Stockholders, featuring proposals for director elections, an amended incentive compensation plan, and executive compensation advisory votes.

Summary

• Glaukos Corporation is holding its 2024 Annual Meeting of Stockholders on May 30, 2024.
• Stockholders of record as of April 5, 2024, are eligible to vote.
• Key proposals include the election of three Class III directors, approval of an amended and restated 2015 Omnibus Incentive Compensation Plan, advisory votes on executive compensation frequency and approval, and ratification of Ernst & Young LLP as the independent registered public accounting firm.
• The Board of Directors recommends voting for all director nominees, the amended incentive plan, annual advisory votes on executive compensation, approval of executive compensation, and ratification of the accounting firm.
• The company's mission is to transform vision by pioneering novel, dropless platforms for sight-threatening chronic eye diseases, with innovation at its core.
• Glaukos reported net sales of $315 million and cash and equivalents of $301 million as of December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook for Glaukos, highlighting strong financial results, pipeline advancements, and a commitment to sustainability and corporate governance. The tone is optimistic and confident, reflecting the company's belief in its ability to execute its long-term strategy and create value for stockholders.

Positives

• The company's Board of Directors is composed of a majority of independent directors.
• The company has a strong focus on diversity, with 38% of directors being women and 25% self-identifying as members of an underrepresented community.
• The company has a robust stockholder engagement process, with proactive semiannual engagement with stockholders and incorporation of stockholder feedback into strategies and programs.
• The company has a clawback policy in place.
• The company has a stock ownership policy applicable to directors and executive officers.
• The company has anti-pledging and anti-hedging policies in place.
• The company has a written code of business conduct and ethics.
• The company has a Sustainability Council focused on topics material to the company and its stakeholders.
• The company has a strong focus on cybersecurity, with 100% of Glaukos users completing cybersecurity training and an external consultant performing a gap assessment of the cybersecurity program.

Negatives

• The company's adjusted non-GAAP operating expenses in 2023 were approximately $360.0 million, which was 2.5% above the annual budget target.

Risks

• The document contains forward-looking statements that are subject to risks and uncertainties, including the impact of the COVID-19 pandemic, macroeconomic conditions, reimbursement rates, and the company's ability to generate sales and develop new products.
• The company is dependent on a limited number of third-party suppliers, some of which are single-source, for components of its products.
• The company's primary facility could be affected by a crippling accident, natural disaster, or other disruption, which may materially affect its manufacturing capacity and operations.
• The company's products may not receive adequate coverage or reimbursement by third-party payors.
• The company may not be able to properly train, and gain acceptance and trust from ophthalmic surgeons in the use of its products.
• The company may not be able to compete effectively in the medical device industry, and against current and future technologies (including MIGS technologies).
• The company may not be able to comply with federal, state and foreign laws and regulations for the approval and sale and marketing of its products and of its manufacturing processes.
• The company's clinical trials may be lengthy and expensive, and the timing and outcomes from any particular clinical trial or regulatory approval processes may be uncertain.
• The company's products may be subject to recalls or serious safety issues, and patient outcomes may be uncertain.
• The company may not be able to protect its intellectual property against third parties and competitors, and may be subject to claims for infringement or misappropriation of third party intellectual property rights and any related litigation.
• The company may not be able to achieve its environmental, social and governance goals.
• The company may not be able to service its indebtedness.

Future Outlook

The company anticipates a transformative period ahead, driven by the commercialization of iDose TR and advancements in its product pipeline.

Management Comments

• Our mission at Glaukos is to truly transform vision by pioneering novel, dropless platforms that can meaningfully advance the standard of care and improve outcomes for patients suffering from sight-threatening chronic eye diseases.
• Innovation is at the core of everything we do.
• Our mantra Well Go First embodies our commitment and determination to take chances, push the limits of science, and disrupt the legacy treatment paradigms in glaucoma, corneal disorders, and retinal diseases through our pursuit of game-changing technologies.
• Our strong business foundation and talented teams around the globe give us confidence in our continued ability to execute our long-term strategy and advance our mission for the benefit of patients worldwide.

Industry Context

Glaukos operates in the ophthalmic pharmaceutical and medical technology industry, focusing on developing and commercializing novel therapies for glaucoma, corneal disorders, and retinal diseases.

Comparison to Industry Standards

• The document references a peer group of 18 companies in the life sciences sector used for benchmarking executive compensation, including Aerie Pharmaceuticals, Axonics, and Nevro.
• The company compares its Information Security Program with industry standards including the National Institute of Standards and Technology Cybersecurity Framework (NIST CSF) and ISO 27001, and is working toward formal alignment with NIST standards by 2025.

Corporate Governance

Related Party Transactions

• The son of Thomas W. Burns, our Chairman and CEO, is an employee of the Company and his 2023 compensation, consisting of base salary, bonus and target long-term incentive compensation equity grant, was approximately $160,000.
• Additionally, Mr. Burns daughter became an employee of the Company in 2024, and it is anticipated that her 2024 compensation, also consisting of base salary, bonus and target long-term incentive compensation equity grant, will be approximately $170,000.

Stakeholder Impact

• The company's sustainability efforts aim to improve its societal, environmental, and community impact, benefiting employees, customers, patients, investors, and communities.
• The company's executive compensation program is designed to align the interests of executives with those of stockholders, creating long-term value for stockholders.
• The company's patient access programs aim to ensure that patients worldwide who suffer from sight-threatening diseases such as glaucoma or keratoconus can benefit from the company's products regardless of inability to pay or lack of information.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the proxy statement.
• The company will continue to engage with stockholders and review its corporate governance structure.
• The company will continue to advance its product pipeline and commercialize iDose TR.

Key Dates

Keywords

executive compensation, corporate governance, annual meeting, director elections, incentive plan, sustainability, financial results, Glaukos